Dianthus Therapeutics, Inc. (DNTH)
NASDAQ: DNTH · Real-Time Price · USD
19.15
-1.24 (-6.08%)
At close: Aug 7, 2025
Ligand Pharmaceuticals Stock Forecast
Stock Price Forecast
The 6 analysts that cover Ligand Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $53, which forecasts a 176.76% increase in the stock price over the next year. The lowest target is $36 and the highest is $84.
Price Target: $53.00 (+176.76%)
Analyst Consensus: Strong Buy
* Price targets were last updated on May 13, 2025.
Analyst Ratings
The average analyst rating for Ligand Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 3 | 3 | 3 | 3 |
| Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| William Blair | William Blair | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Jul 2, 2025 |
| Baird | Baird | Buy Maintains $58 → $50 | Buy | Maintains | $58 → $50 | +161.10% | May 13, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $40 | Strong Buy | Reiterates | $40 | +108.88% | May 13, 2025 |
| Wedbush | Wedbush | Buy Reiterates $36 | Buy | Reiterates | $36 | +87.99% | Mar 12, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates $84 | Strong Buy | Reiterates | $84 | +338.64% | Mar 12, 2025 |
Financial Forecast
Revenue This Year
3.83M
from 6.24M
Decreased by -38.60%
Revenue Next Year
3.25M
from 3.83M
Decreased by -15.13%
EPS This Year
-3.40
from -2.55
EPS Next Year
-3.64
from -3.40
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 7.1M | 7.5M | 54.9M | ||
| Avg | 3.8M | 3.2M | 9.6M | ||
| Low | 1.1M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 14.4% | 95.6% | 1,591.0% | ||
| Avg | -38.6% | -15.1% | 194.6% | ||
| Low | -81.7% | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -2.64 | -3.06 | -3.07 |
| Avg | -3.40 | -3.64 | -3.96 |
| Low | -3.70 | -4.45 | -5.80 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.